Cipla announced that it has entered into an India-specific strategic partnership with Merck’s Indian unit, MSD Pharma.

Cipla revealed that it has yet to arrive at a price for the drug, though it is confident that its extensive marketing operations and expertise in HIV/AIDS segment will help it to promote the drug’s availability in the country.
“This partnership reinforces Cipla’s ongoing commitment to HIV/AIDS treatment making life-saving drugs accessible. Raltegravir, a third line therapy treatment, will be a value-addition to Cipla’s portfolio of HIV/AIDS treatment, especially for those patients who are resistant to the first and second line therapy treatment,”, the chief medical officer at Cipla, Jaideep Gogtay said.
Source-Medindia